Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1998 with a focus on developing and commercializing new oncology therapeutics for hematologic and solid tumor cancers. The company's commitment to advancing oncology treatment and patient care is evident in its emphasis on its novel kinase-inhibitor pipeline, particularly the oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), for the treatment of ibrutinib-resistant chronic lymphocytic leukemia. Sunesis has received a significant $25.00M Post-IPO Equity investment on 19 October 2016. As a biopharmaceutical company in the United States, Sunesis has built an experienced cancer drug development organization determined to improve the lives of people with cancer. The company's dedication to translational and clinical science, creating a teamwork-oriented workplace, and supporting the larger oncology community and philanthropic organizations underscores its commitment to making a meaningful impact in the field of oncology.